Rallybio

Rallybio is a clinical-stage biotech company committed to delivering groundbreaking therapies with the potential to truly transform the lives of millions of patients with devastating rare diseases. The company focuses on complement dysregulation and hematology, with a pipeline of assets that have best-in-class potential. Rallybio's team includes innovators with a track record of success in translating scientific breakthroughs into life-changing treatments.

Rallybio is a clinical-stage biotech company committed to delivering groundbreaking therapies for patients with rare diseases. The company's goal is to change the narrative for patients with rare diseases, tackling the undone, the too difficult, and the inaccessible. Rallybio's pipeline includes assets in complement dysregulation and hematology, with the RLYB116 confirmatory PK/PD study expected to provide evidence that its C5 inhibitor has the potential to be best-in-class for patients with complement-mediated diseases.

1. 1Rallybiorallybio.com
2. 2About Us | Rallybiorallybio.com
3. 3Rallybiowikidata.org